Here we briefly overview the discovery, tissue distribution, and subcellular localization of HSD17B13 and highlight its important role in promoting the pathogenesis of NAFLD/NASH in both experimental animal models and patients. Here, HSD17B13 is linked to metabolic dysfunction-associated steatotic liver disease.